Case reports and early trials involving anti‐CD19 and anti‐BCMA CAR‐T in CNS autoimmune disorders (such as NMOSD, MG, and stiff‐person syndrome) have reported manageable safety profiles and clinical improvement, although data on pure AE remain limited [64]. Here, CD19 is linked to myasthenia gravis.